New primary monoclonal antibodies

New primary monoclonal antibodies · 16. April 2025

SYnAbs unique R&D and therapeutic monoclonal antibodies to CCR10 (GPR-2), C-C chemokine Receptor 10 GPCR transmembrane protein

New primary monoclonal antibodies · 10. April 2025

Valproic acid (VPA) is a widely used drug with narrow therapeutic window, necessitating precise monitoring of blood levels to avoid toxicity or sub-therapeutic effects. Traditional methods of measuring VPA have limitations in terms of sensitivity, specificity, and accuracy. In this context, SYnAbs has developed the best monoclonal antibodies against VPA.

New primary monoclonal antibodies · 02. October 2024

SYnAbs develops monoclonals to complex cancer epitopes to be used in theranostic oncology radioimmunotherapy treatments

New primary monoclonal antibodies · 24. April 2023

CRP is synthesized by the liver in response to several inflammatory cytokines and is a well-established biomarker of inflammation and infection. Elevated CRP levels are associated with several diseases, including inflammatory bowel disease, rheumatoid arthritis, cardiovascular disease, infection, and cancer. SYnAbs Monoclonal antibodies offer several advantages for CRP diagnosis in a precision medicine context.

New primary monoclonal antibodies · 25. November 2022

Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins